文献速递银屑病与炎症性皮肤病

富马酸酯在银屑病患者中的长期真实世界安全性特征与有效性:一项单中心、回顾性、观察性研究

Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-05-18

该单中心回顾性观察性研究纳入859例德国银屑病患者,随访长达32.5年,评估富马酸酯(FAEs)单药或联合光疗/甲氨蝶呤的长期安全性与有效性。49.0%患者报告不良事件,2.3%发生严重不良事件且均判定与治疗方案无因果关系;三种方案达到PGA 50%应答的中位时间均为1年,而PASI 75累积应答中位时间单药为3年、联合光疗6.7年、联合甲氨蝶呤8.1年(P=0.001)。作者认为FAEs单药或联合治疗长期使用安全有益,但需多中心随机对照试验进一步确立临床价值。

要点

  • 49.0%患者报告不良事件,以胃肠道为主;严重不良事件2.3%,均判定与治疗无因果关系。
  • 12.9%患者因不良事件停药。
  • 三种方案达到PGA 50%应答的中位时间均为1年(P=0.70)。

核心结论

  • 根据本研究数据,FAEs单药或联合光疗或甲氨蝶呤长期临床使用安全且有益。
  • 需多中心随机对照试验以确立单药与联合治疗的临床价值及最佳治疗时长。

研究设计与样本

  • 单中心、回顾性观察性研究,随访期长达32.5年,纳入859例德国银屑病患者。
  • 626例接受FAE单药治疗,123例接受FAEs联合光疗,110例接受FAEs联合甲氨蝶呤。

主要发现

  • 约半数患者(49.0%)报告不良事件,共566起事件,多数累及胃肠道。
  • 2.3%患者报告严重不良事件,但均判定与任何治疗方案无因果关系。
  • 12.9%患者因不良事件导致治疗中断。
  • 三个治疗亚队列从启动FAE治疗至50%应答率的中位时间均为1年(P=0.70),应答定义为累积静态PGA评分为「light」且基线PGA至少降低2分。
  • 累积PASI 75的50%应答率中位时间:FAE单药亚队列3年,FAEs+光疗亚队列6.7年,FAEs+甲氨蝶呤亚队列8.1年(P=0.001)。

局限性

  • 需多中心随机对照试验以确立单药与联合治疗的临床价值及最佳治疗时长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fumaric acid esters (FAEs) are an established systemic treatment for moderate-to-severe psoriasis. However, the long-term clinical safety and effectiveness of continuous FAE monotherapy and combination therapy have not been established. OBJECTIVE: To examine the long-term safety and effectiveness of FAEs as monotherapy and in combination with phototherapy or methotrexate in patients with psoriasis treated at a single centre in Germany. METHODS: This monocentric, retrospective observational study, with a follow-up period of up to 32.5 years, included 859 patients: 626 received FAE monotherapy, 123 received FAEs with concomitant phototherapy and 110 received FAEs with methotrexate. RESULTS: Approximately half of patients (49.0%) reported adverse events (566 total events), most of which involved the gastrointestinal tract. Serious adverse events were reported in 2.3% of patients, but none were deemed to have a causal relationship with any of the treatment regimens. Adverse events leading to treatment discontinuation were observed in 12.9% of patients. A median duration of 1 year was observed in all three treatment subcohorts (P = 0.70) from initiation of FAE treatment to a 50% response rate, where response was defined as achieving a cumulative static Physician's Global Assessment (PGA) score of 'light' and at least a 2-point reduction in baseline PGA. A 50% response rate for the cumulative Psoriasis Area and Severity Index 75 was achieved in the FAE monotherapy subcohort after a median of 3 years of treatment, in the FAEs + phototherapy subcohort after 6.7 years and in the FAEs + methotrexate subcohort after 8.1 years (P = 0.001). CONCLUSION: According to our data, FAEs as monotherapy or in combination with phototherapy or methotrexate are safe and beneficial for long-term clinical use. However, multicentre, randomized controlled trials are required to establish the clinical value of monotherapy versus combination therapy and the optimal treatment duration.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Dickel H, Bruckner T, Altmeyer P, et al. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study. J Eur Acad Dermatol Venereol. 2018. PMID: 29705996. doi:10.1111/jdv.15019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。